QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 7.0499
-- x --
-- x --
-- - --
$ 1.75 - $ 72.50
995
na
na
$ 7.89
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 abivax-stock-skyrockets-on-strong-data-from-inflammatory-bowel-disorder-study

Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favo...

 palatin-technologies-announces-transition-to-otc-pink-market-under-ticker-symbol-ptnt-beginning-on-may-8-2025

The Company Intends to Request a Review of the Delisting DeterminationCRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Techn...

 palatin-announces-it-expects-115m-financing-to-remedy-nyse-american-delisting-notice

Funding Supports Advancement of Obesity Program and Strategic Business Development InitiativesAdvancement of novel next-generat...

 palatin-technologies-prices-23m-public-offering-of-76666667-shares-at-015share

$11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants

 palatin-technologies-announced-updated-results-from-responder-analyses-of-its-pivotal-phase-3-melody-1-trial-evaluating-the-safety-and-efficacy-of-pl9643-versus-placebo-for-dry-eye-disease

Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye dis...

 palatin-technologies-announces-positive-appetite-suppression-results-from-bmt-801-phase-2-obesity-study

Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite sup...

 palatin-technologies-appeals-nyse-delisting-decision-seeks-to-regain-compliance-in-90-days

Palatin Technologies, Inc. (the "Company") (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines ...

 palatin-technologies-reports-71-of-patients-achieved-30-upcr-reduction-in-phase-2b-diabetic-kidney-study

Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 dia...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION